Mylan Indapamide

Quick links to important sections

Mylan Indapamide

Treatment option: Hypertension

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mylan Indapamide

Property Description
Active ingredient Indapamide
Form Tablet (Oral administration)
Pharmacological class Thiazide-like Diuretic, Antihypertensive
Common use Blood pressure reduction
Origin Synthetic (Non-thiazide Sulfonamide)

Mylan Indapamide is a prescription-only synthetic medicine containing the active ingredient Indapamide, which is primarily used to manage conditions related to excess fluid and high blood pressure. This medicine is formally classified as a thiazide-like diuretic and an antihypertensive agent. Clinical consensus recognizes that this agent provides benefits in the long-term management of elevated blood pressure, confirming its foundational role in circulatory system management.


What Type of Medicine is Mylan Indapamide? (Identity and Classification)

Mylan Indapamide is a specific presentation of Indapamide, a type of diuretic (often called a "water pill") that helps the body regulate fluid balance, and it is chemically recognized as a non-thiazide sulfonamide. This specific formulation, distributed by Mylan Pharmaceuticals (now part of Viatris), provides a standardized oral tablet version of the substance. While its main function involves increasing the excretion of salt (sodium) and water by the kidneys, Indapamide is distinct from many common diuretics because it possesses a dual physiological mechanism. It acts not only on the kidney function but also directly influences the walls of the blood vessels, causing them to relax.


Indapamide: Composition, Form, and General Purpose

The medication is a single-ingredient product presented for oral administration in the form of a tablet. Each tablet contains Indapamide as the sole active pharmaceutical component, alongside solid oral excipients necessary for the tablet's structure. The general purpose of this medicine is to utilize its dual action—fluid removal and vessel relaxation—to consistently reduce resistance and volume in the circulatory system. By achieving this, it helps to lower high pressure exerted on the artery walls, which is the foundational therapeutic goal of an antihypertensive agent.

Regulatory References

  1. Indapamide: MedlinePlus Drug Information

What side effects are possible with Mylan Indapamide?

Possible Side Effects and Safety Information

The safety profile of Indapamide is documented based on official regulatory classifications, detailing possible adverse reactions and restrictions on use. The most frequently observed effects relate to the medicine's diuretic function, impacting fluid and electrolyte balance. This necessitates regulatory monitoring of vital minerals such as potassium (Hypokalemia) and sodium (Hyponatremia), which are classified as common adverse reactions.

Adverse effects are formally grouped by the body system affected, according to System-Organ Classes (SOCs):

Classification Examples of Documented Effects
Common (1% to < 10%) Headache, Dizziness, Fatigue, Muscle cramps, Hypokalemia, Skin rash.
Rare (0.01% to < 0.1%) Acute Pancreatitis, Paresthesia, Bone marrow depression, Hypercalcemia.
Very Rare (< 0.01%) Hepatic encephalopathy, Acute renal failure, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN).
Incidence Not Known Acute Angle-Closure Glaucoma, Acute Myopia, Visual impairment.

Serious Adverse Reactions officially noted include life-threatening cardiac arrhythmias such as Torsade de pointes associated with severe hypokalemia, and acute ocular emergencies like Acute Angle-Closure Glaucoma linked to its sulfonamide-derivative structure.

Population-Specific Safety Notes specify that the medicine is contraindicated in conditions such as severe renal or hepatic impairment, pre-existing severe hypokalemia, and known hypersensitivity to sulfonamide drugs. Elderly patients are formally identified as being at higher risk for severe electrolyte imbalance. Furthermore, official labeling states that the risk of certain effects, such as increased urination and changes in renal function, is more likely to occur at the start of treatment.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Mylan Indapamide


Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations Symptoms are an exaggeration of the drug's effects, primarily manifesting as severe fluid and electrolyte disturbances [Source: FDA Prescribing Information]. Signs include hypotension (excessively low blood pressure), oliguria (reduced urine output), nausea, vomiting, and neurological signs such as drowsiness, lethargy, or restlessness [Source: FDA Prescribing Information].
Physiological Systems Affected (as stated in label) The Cardiovascular System (hypotension, tachycardia, arrhythmias), Central Nervous System (drowsiness), Renal System (oliguria, fluid/electrolyte imbalance), and Hepatic System (risk of hepatic coma) are officially noted as affected [Source: EMA SmPC; FDA Prescribing Information].
Dose-related or Exposure-related Factors (if applicable) Overdose results from excessive exposure, leading to profound fluid and electrolyte loss and subsequent severe Hypovolaemia/Dehydration [Source: EMA SmPC; Health Canada Product Monograph].
Population-specific Overdose Notes (if applicable) Elderly patients face an increased risk of severe hyponatremia (low sodium) and hypokalemia (low potassium) [Source: FDA Prescribing Information]. Patients with pre-existing impaired hepatic function are at risk of overdose-induced hepatic encephalopathy or coma [Source: EMA SmPC].
Emergency-response statements (as written in official documents) Management is strictly symptomatic and supportive, focusing on the correction of fluid and electrolyte abnormalities; procedures may involve intravenous fluid replacement [Source: EMA SmPC; FDA Prescribing Information]. No specific antidote is known [Source: Regulatory consensus].
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention for any suspected overdose [Source: NIH MedlinePlus]. Contact emergency services (e.g., 911) immediately if the affected person collapses, has a seizure, has trouble breathing, or cannot be awakened [Source: NIH MedlinePlus].

Overdose Classifications (High-Level)

Classification Official Regulatory Wording / Basis
Severity classification (as defined in official documents) The profile includes manifestations classified as severe or life-threatening, specifically severe hypotension and fatal cardiac dysrhythmias secondary to hypokalemia [Source: Health Canada Product Monograph].
Regulatory basis (EMA / FDA / etc.) The overdose profile is compiled from the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC) [Source: Multiple regulatory documents].
Overdose-context constraints (as defined in official documents) Procedures require close monitoring and laboratory assessment of serum electrolytes for extended periods [Source: FDA Prescribing Information].

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile by its acute physiological consequences, detailing manifestations that arise directly from severe fluid and electrolyte loss, such as hypotension and hypokalemia. These consequences, particularly in vulnerable populations such as the elderly, necessitate explicit emergency-seeking conditions which mandate immediate medical attention and the initiation of supportive treatments focused on correcting the severe imbalances.

Therapeutic Uses of Mylan Indapamide

What Mylan Indapamide Treats: Main Uses and Benefits

Mylan Indapamide is primarily used to address two key areas of systemic imbalance, both of which are relevant in contexts involving heightened systemic burden. This medication is indicated for treating hypertension and managing fluid retention (edema).


Management of Sustained High Blood Pressure

The medication is commonly used to help with Essential Hypertension, a condition characterized by periods of heightened symptoms of systemic pressure elevation. This continuous treatment contributes to easing the long-term strain on the heart and blood vessels. By lowering and maintaining blood pressure, it may assist with reducing the likelihood of serious cardiovascular events, such as stroke and heart attack, thereby helping to ease the overall symptom load. It is used for managing conditions such as Essential Hypertension and edema associated with Congestive Heart Failure.

“It provides support that helps ease the overall symptom burden, particularly in chronic conditions requiring long-term pressure management.”


Relief of Fluid Retention (Edema) in Volume Overload

Mylan Indapamide is also relevant for easing symptoms related to systemic imbalance, specifically by relieving fluid retention in conditions like Congestive Heart Failure. It is applied in addressing the symptoms that create noticeable physiological strain caused by fluid accumulation, providing support that helps ease the overall burden of symptoms. This action supports the patient during difficult episodes and helps improve day-to-day comfort.


Quick Fact: Relief for Pathological Fluid Retention

  • Symptom Domain: Symptoms related to systemic imbalance and fluid accumulation.
  • Benefit: Contributes to improved comfort during symptomatic periods by reducing swelling.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Mylan Indapamide is a prescription medicine primarily intended for most adults aged 18 and over who do not have specific pre-existing conditions. Official regulatory labeling defines strict eligibility rules for its use, particularly excluding specific high-risk populations.

Absolute Contraindications (Must Not Use)

  • Hypersensitivity: Patients with an allergy to Indapamide or to any other sulfonamide-derived drugs.
  • Severe Organ Dysfunction: Individuals with severe renal failure (creatinine clearance below 30 mL/min) or severe impairment of liver function, including hepatic encephalopathy.
  • Electrolyte Imbalance: Patients with existing Hypokalaemia (abnormally low potassium levels in the blood) or Anuria (inability to pass urine).

Population-Specific Restrictions

  • Pediatric Use: The medicine is not recommended for use in children and adolescents (under 18 years of age) because its safety and effectiveness have not been established in this age group.
  • Pregnancy and Lactation: Use is generally contraindicated or not recommended during pregnancy and breastfeeding.
  • Geriatric Use: Elderly patients can be treated, but dose selection must be cautious, reflecting a greater frequency of decreased organ function and increased risk of severe hyponatremia.
  • Caution Required: Patients with conditions like gout, diabetes mellitus, or Systemic Lupus Erythematosus (SLE) require careful monitoring if treated with Indapamide, as stated in the label.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify Indapamide's interactions primarily based on two mechanisms: pharmacodynamic effects on electrolytes and the renal excretion of co-administered agents.

Interaction Classification Documented Interactions (Regulatory)
Contraindicated Combinations Torsades de pointes-inducing anti-arrhythmic agents (due to increased risk of ventricular arrhythmias, exacerbated by hypokalemia); Aliskiren (in patients with diabetes, due to increased risk of renal impairment).
Major Interaction Risk Lithium: Indapamide reduces its renal clearance, which mandates close plasma Lithium monitoring and possible dose adjustment to prevent toxicity.
Exposure and Efficacy Modifying Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including high-dose acetylsalicylic acid (ge 3 g/day): Risk of loss of antihypertensive effect and acute renal impairment. Simvastatin dose is restricted to not exceed 20 mg daily when co-administered.
Additive Effects Other potassium-lowering agents (e.g., systemic corticosteroids, stimulant laxatives): Increased risk and severity of hypokalemia. Alcohol, barbiturates, or narcotics: May potentiate orthostatic hypotension.
Population-Specific Notes Elderly females (ge 65 years) have a reported increased risk of severe hyponatremia/hypokalemia. Close monitoring of blood glucose is advised for diabetic patients.

This interaction profile requires specific clinical constraints, including the avoidance of specific cardiac drugs, careful monitoring of electrolytes and renal function, and dose limitations for certain cholesterol-lowering agents.

Mechanism of Action

Modulation of Renal Salt and Water Transport

The drug's action is defined by a dual mechanism that influences two primary determinants of circulatory pressure: fluid volume and peripheral vessel resistance. The first domain targets the sodium-chloride cotransporter ( SLC12A3) in the kidney's distal convoluted tubule. By inhibiting this transport protein, Indapamide prevents sodium and chloride reabsorption, which initiates a cascade that retains water in the urinary system. This mechanism produces increased salt and water excretion, which decreases the total intravascular fluid volume.

Direct Vasorelaxant Effect on Arterial Tone

The second, independent domain involves a direct effect on vascular smooth muscle cells of the arteries, where the drug modulates calcium dynamics. This action causes the muscle fibers to relax and the vessels to widen ( vasodilation). This mechanism produces a decrease in Total Peripheral Resistance ( TPR), which constitutes the non-volume-dependent component of the drug's influence on circulatory mechanics. The combined action of volume reduction and resistance reduction results in a dual systemic physiological change that engages the core mechanisms determining circulatory pressure.

Dosage and Administration Information

How to Use Mylan Indapamide: Official Administration Guidelines

Mylan Indapamide is prescribed as an oral tablet for continuous, long-term administration. The usage protocol is defined by specific guidelines concerning dose, frequency, and timing.


Official Dosing and Frequency

The standard frequency for Indapamide is once daily. The tablet should ideally be taken in the morning to prevent disruption from increased urination at night. It may be taken with or without food.

Clinical Use Initial Dose (Once Daily) Maximum Dose (Once Daily) Adjustment Interval
Hypertension (High Blood Pressure) 1.25 mg Generally 5 mg After 4 weeks
Edema (Fluid Retention) 2.5 mg Generally 5 mg After one week

Administration Requirements

Indapamide tablets must be swallowed whole with water; they should not be crushed, broken, or chewed, particularly in the case of slow-release formulations.

For patients with chronic conditions like essential hypertension, Indapamide is typically used as part of a long-term treatment plan. If a dose is missed, patients should simply take the next scheduled dose at the usual time and should not take a double dose to compensate.

Indapamide is not recommended for use in children and adolescents under 18 years of age, as data on safety and effectiveness in this population are unavailable.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Mylan Indapamide

Mylan Indapamide, which contains the active ingredient Indapamide, has been the focus of extensive scientific research, primarily in the form of large, high-quality Randomized Controlled Trials (RCTs). These studies are designed to explore how the compound Indapamide is associated with different outcomes in regulated settings. This summary describes the landscape of that research, focusing only on the types of studies conducted and the general patterns they were designed to measure, without offering clinical advice or making personal predictions.


Evidence for Use in Essential Hypertension (High Blood Pressure)

The foundational research for Indapamide's use involves large-scale, long-term clinical trials that included thousands of participants. These studies were specifically designed to measure changes in blood pressure levels in adults diagnosed with hypertension. Trials also monitored the occurrence of major health events, such as fatal and non-fatal stroke and heart attack, to explore long-term risk patterns in the observed groups. Research reports patterns related to how blood pressure measurements evolved in the observed populations and documented the rates of cardiovascular events during the study period.

Evidence regarding patterns related to cardiovascular events often comes from research where Indapamide was studied in combination with another compound, rather than alone (monotherapy). The evidence describes patterns observed in these combination-treatment settings, but the extent of its independent, long-term effect is not as fully characterized as its role in multi-drug regimens.


Evidence for Secondary Prevention of Stroke and Vascular Events

A major area of research has been the use of Indapamide in studies focusing on secondary risk patterns. This means research has focused on people who have already experienced a serious event, such as a stroke or Transient Ischemic Attack (TIA), and are at high risk for another.

These long-term randomized controlled trials were conducted in high-risk populations over several years. Researchers examined the incidence of recurrent stroke, as well as other serious outcomes, including vascular death. Research reports patterns related to the occurrence of subsequent events in individuals who were monitored under the specific conditions of the trial. The reported patterns in secondary risk studies were derived from research where Indapamide was studied as part of a combination treatment.


Evidence for Fluid Retention (Edema) in Heart Failure

The compound was also evaluated in research settings exploring fluid retention (edema), a symptom often associated with conditions like Congestive Heart Failure. These studies typically employed short-term clinical trials or comparative effectiveness studies, often comparing Indapamide to other established diuretic compounds. Research in this area focused on outcomes related to fluid volume reduction, such as changes in body weight and the measurable level of swelling. The evidence describes symptom patterns observed in the research, but it does not include the same type of large-scale, long-term mortality tracking that exists for the hypertension indication.

Key Studies & References

  1. Indapamide Tablets USP: Prescribing Information (DailyMed)
  2. Hypertension in adults: diagnosis and management (NICE Guideline NG136)

Frequently Asked Questions (FAQ)

Common questions about Mylan Indapamide (FAQ)


Q: How long does it usually take to notice the effects of Mylan Indapamide?

Official product documents indicate that the lowering of blood pressure, known as the antihypertensive effect, is typically apparent within 2 weeks of starting the daily treatment regimen. The official documentation indicates that the main effects on blood pressure measurements become visible relatively soon after beginning therapy. This quick timeframe is a characteristic noted in the drug's official profile.


Q: How is Indapamide different from other common blood pressure medicines?

Official product information describes Indapamide as having a dual mechanism of action. It acts as a diuretic (a water pill) by increasing salt and water excretion, and it also has an extrarenal mechanism that directly reduces resistance in blood vessel walls. This combined action on both fluid volume and blood vessel relaxation helps distinguish it from some other common blood pressure treatments.


Q: Does Mylan Indapamide treat conditions other than high blood pressure?

Yes, regulatory documents indicate that in addition to treating hypertension (high blood pressure), the medicine is also formally indicated for the treatment of edema (fluid retention). Edema is the medical term for fluid retention that can sometimes be associated with conditions like heart failure.


Q: Is Mylan Indapamide the same as or similar to hydrochlorothiazide?

Mylan Indapamide is formally classified as a thiazide-like diuretic, meaning it shares key functional characteristics with the thiazide class, which includes hydrochlorothiazide. Clinical study data is available which may compare its effects, particularly on potassium levels, to hydrochlorothiazide.


Q: Does Mylan Indapamide cause dehydration?

Because the medicine works by increasing the excretion of water and salt, official product information advises caution regarding the possibility of fluid or electrolyte imbalance. Official guidance notes caution regarding use if a person is already experiencing dehydration or excessive fluid loss from vomiting, diarrhea, or heavy sweating.


Q: Is it necessary to drink extra water while taking Mylan Indapamide?

While taking the medicine, it is recommended in official guidance to drink enough water during periods of heavy physical activity or in hot weather. This practice may help address lightheadedness or dizziness that can be related to a temporary drop in blood pressure.


Q: What do clinical trials say about the effectiveness of Indapamide?

Clinical trial results show that almost all of the antihypertensive effect is typically apparent within 2 weeks of initiating treatment. This initial quick action is the primary measure of effectiveness noted in the official regulatory documentation.


Q: Is there long-term evidence for the safety of Mylan Indapamide?

Official product information confirms this medicine is used as a long-term therapy, and safety is an ongoing consideration. For this reason, regulatory guidance specifies that serum electrolytes and other blood levels are monitored at regular intervals during long-term use.


Q: Do studies support the use of Indapamide for heart failure?

The official indications for this medicine include the treatment of edema (fluid retention). Since fluid retention is a common symptom associated with conditions like heart failure, the medicine is used to manage this specific fluid buildup as defined in regulatory documents.


Q: Does Mylan Indapamide affect my blood sugar levels?

Official product information states that the medicine generally exerts a minimal effect on overall glucose metabolism. However, in certain individuals, particularly those with latent diabetes, official documents indicate it may potentially lead to hyperglycemia (high blood sugar) and glycosuria (sugar in the urine).


Q: How does Mylan Indapamide impact cholesterol levels?

Official studies examining Indapamide’s action indicate that the medicine does not appear to alter lipid metabolism in patients being treated for hypertension. This means the compound is generally associated with a neutral effect on cholesterol levels, including triglycerides, LDL-cholesterol, and HDL-cholesterol.


Q: Does Mylan Indapamide cause changes in mood or sleep?

The medicine is not officially documented to cause changes in general mood or sleep patterns. However, official product information does list anxiety and drowsiness as side effects that may occur, although they are noted as less common.


Q: How often do people typically need blood tests when taking Mylan Indapamide?

Official guidance indicates that blood tests to monitor serum electrolytes (such as sodium and potassium) are performed at regular intervals. The first measurement of plasma potassium is specifically advised during the first week after starting treatment.


Q: What are the signs of a serious side effect from Mylan Indapamide?

Official safety warnings describe patterns observed in potential severe electrolyte imbalance, which may include confusion, muscle cramps, or an irregular heartbeat. Warnings for a serious eye problem include blurred vision, eye pain, or any sudden change in vision.


Q: Can Mylan Indapamide affect the ability to drive or operate machinery?

Official health guidance indicates that caution is necessary when driving or operating machinery until an individual knows how the medicine affects them. Because the medicine can cause side effects like dizziness, lightheadedness, or fainting, it may temporarily impact alertness or coordination.


Q: How does the body get rid of Mylan Indapamide?

The process by which the body removes the medicine is detailed in the official product information. Approximately 70% of the administered dose is eliminated by the kidneys (via urine), and about 23% is eliminated through the gastrointestinal tract (via feces).


Q: Does Mylan Indapamide show up on standard drug tests?

Official warnings state that the active ingredient, Indapamide, may be detected in the body in a way that gives a positive reaction in doping tests. This is a specific precaution noted for athletes and individuals subject to professional drug screening.

How should Mylan Indapamide be stored and disposed of?

How to Store and Dispose of Mylan Indapamide

Mylan Indapamide tablets must be stored according to regulatory requirements to ensure product integrity.


Storage Requirements

The medicine requires storage at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The tablets must be protected from light and moisture. Store the product in its original container and keep it tightly closed when not in use. As a mandatory safety measure, the medicine must be kept out of the reach and sight of children.


Disposal Instructions

Unused or expired Mylan Indapamide must not be disposed of by throwing it into household waste or flushing it down a drain/toilet (wastewater). Disposal must strictly be performed in accordance with local requirements established for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mylan Indapamide found in:

A-Z Index: